CytomX Therapeutics, Inc.
CTMX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $31,869 | -$569 | -$99,317 | -$83,609 |
| Dep. & Amort. | $1,768 | $2,175 | $5,856 | $2,706 |
| Deferred Tax | $0 | $0 | $0 | $272 |
| Stock-Based Comp. | $7,668 | $0 | $0 | $13,167 |
| Change in WC | -$126,415 | -$62,509 | -$30,654 | -$54,700 |
| Other Non-Cash | -$1,121 | $4,868 | $13,327 | $3,133 |
| Operating Cash Flow | -$86,231 | -$56,035 | -$110,788 | -$119,031 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$310 | -$840 | -$1,740 | -$1,609 |
| Net Acquisitions | $0 | $0 | $0 | -$24,098 |
| Inv. Purchases | -$155,490 | -$424,834 | $0 | -$99,898 |
| Inv. Sales/Matur. | $255,500 | $275,000 | $100,000 | $123,996 |
| Other Inv. Act. | $0 | $0 | $0 | $24,098 |
| Investing Cash Flow | $99,700 | -$150,674 | $98,260 | $22,489 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $6,909 | $30,230 | $648 | $107,712 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $613 | $0 | $0 | $2,501 |
| Financing Cash Flow | $7,522 | $30,230 | $648 | $110,213 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $20,991 | -$176,479 | -$11,880 | $13,671 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $18,088 | $193,650 | $205,530 | $192,776 |
| End Cash | $39,079 | $17,171 | $193,650 | $206,447 |
| Free Cash Flow | -$86,541 | -$56,875 | -$112,528 | -$120,640 |